SCIENCE

FB918

Indications

Asthma

Mechanism of Action

FB918 is a fully-human antibody drug to target interleukin 33 (IL-33). It was developed by Oneness Biotech by screening a human antibody library, and is now in the pre-clinical development stage. Currently, all the major pharmaceutical companies are enthusiastic in exploring new indications of IL-33 drugs, making IL-33 a promising new drug target.

Current Status

Pre-clinical studies

Market Potentials

Today, the treatment of non-allergic eosinophilic asthma is still an unmet medical need. Patients of this disease show an increase in group II innate lymphoid cells (ILC2), which when stimulated by the IL-33 secreted by epithelial cells cause maturation and migration of eosinophils and thus lead to an attack of the disease. Statistics show that the global market of asthma treatment in 2019 was about USD 18 billion, and the market size is predicted to reach USD 26 billion in 2027.

R&D Progress
Complete
In Progress
Research Code Therapeutic Area Indication Pre-Clinical Phase I Phase II Phase III NDA Market More
  • FB918
    Immunology
    Asthma

    FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for asthma. It has been discovered and developed from Oneness-owned antibody library

關閉

建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。

要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
    開啟新分頁
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
    於搜尋框中打入Edge,並按搜尋
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge